Originally Posted by
Beagle
Forbar have been consistently downbeat on HGH in recent years and have been consistently wrong.
They never rung the bell at the bottom or even tried too.
I am not pretending for one minute I am always right but I put up one of the most emphatic posts on here I have ever made, (rung the bell in other words), in early November 2020 that at ~ $1.30 these were exceptionally good buying and it was time to back up the truck, which is exactly what I did. The outperformance since then has been extraordinary in what has been a flat market overall. All that time Forbar have been really downbeat on HGH and have remained so ever since. Counting dividends received I've nearly doubled my money in 16 months on that truckload so I need a trailer now as well :t_up:
My own work yesterday showed that on a forward FY22 basis HGH is trading in line with its peer group.
For the record:- I was with Forbar for about 10 years on full advisory service. I left more than a decade ago because I thought I could do a lot better with my own analysis than they could, a decision I have never for one minute regretted.
Their claim that HGH is now trading at a premium to its peer group must be predicated upon a very different peer group than I used.
I think their valuation is completely ridiculous. I am happy with my $2.60 price target for March 2023.
I think a famous line from the movie Wall street says it best, "Their analyst wouldn't know preferred stock from livestock".